Showing 221 - 240 results of 394 for search '"breast"', query time: 0.08s Refine Results
  1. 221

    The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis by Edward Li, Bridgette Kanz Schroader, David Campbell, Kim Campbell, Weijia Wang

    Published 2021-06-01
    “…**Methods:** This was a retrospective observational study in patients with breast cancer (BC) who received myelosuppressive chemotherapy and prophylactic pegfilgrastim identified January 1, 2017-May 31, 2018 from MarketScan® research databases. …”
    Get full text
    Article
  2. 222

    Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data by David Weller, Usha Menon, Alina Zalounina Falborg, Henry Jensen, Andriana Barisic, Anne Kari Knudsen, David H Brewster, Victoria Cairnduff, Eva Grunfeld, Elizabeth Harland, Mats Lambe, Rebecca-Jane Law, Yulan Lin, Martin Malmberg, Donna Turner, Richard D Neal, Victoria White, Samantha Harrison, Peter Vedsted, Una MacLeod, Conan Donnelly, Anna Gavin, Jon Emery, Oliver Bucher, Jatinderpal Kalsi, Chantelle Anandan, Evangelia Ourania Fourkala, Therese Kearney, Marie-Louise Essink-Bot, Sigrun Saur Almberg, Breann Hawryluk, Jacqueline Kelly, Jackie Boylan, Jan Willem Coebergh, David Brewster, Stefan Bergström, Victoria Hammersley, Rebecca Bergin, Alina Zalounina Falborg, Andriana Barisi, Kerry Moore, Maria Rejmyr Davis

    Published 2022-12-01
    “…Objectives A growing body of evidence suggests longer time between symptom onset and start of treatment affects breast cancer prognosis. To explore this association, the International Cancer Benchmarking Partnership Module 4 examined differences in breast cancer diagnostic pathways in 10 jurisdictions across Australia, Canada, Denmark, Norway, Sweden and the UK.Setting Primary care in 10 jurisdictions.Participant Data were collated from 3471 women aged >40 diagnosed for the first time with breast cancer and surveyed between 2013 and 2015. …”
    Get full text
    Article
  3. 223

    Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial by Guoshuang Shen, Zhilin Liu, Miaozhou Wang, Yi Zhao, Xinlan Liu, Yujin Hou, Wenbiao Ma, Jingqi Han, Xiaofeng Zhou, Dengfeng Ren, Fuxing Zhao, Zitao Li, Shifen Huang, Yongzhi Chen, Yingjian He, Yan Liu, Zijun Zhu, Yongxin Li, Jinming Li, Mengting Da, Hongnan Mo, Feng Du, Liang Cui, Jing Bai, Zhen Liu, Fei Ma, Jiuda Zhao

    Published 2025-02-01
    “…Abstract We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative breast cancer (TNBC). In the phase 2 NeoSAC trial, patients with early TNBC received six cycles of apatinib, sintilimab, nab-paclitaxel, and carboplatin followed by surgery. …”
    Get full text
    Article
  4. 224
  5. 225
  6. 226
  7. 227
  8. 228
  9. 229
  10. 230
  11. 231
  12. 232
  13. 233
  14. 234
  15. 235
  16. 236
  17. 237
  18. 238

    LncRNA PVT1 links estrogen receptor alpha and the polycomb repressive complex 2 in suppression of pro-apoptotic genes in hormone-responsive breast cancer by Viola Melone, Domenico Palumbo, Luigi Palo, Noemi Brusco, Annamaria Salvati, Antonietta Tarallo, Giorgio Giurato, Francesca Rizzo, Giovanni Nassa, Alessandro Weisz, Roberta Tarallo

    Published 2025-02-01
    “…Abstract RNA-based therapeutics highlighted novel approaches to target either coding or noncoding molecules for multiple diseases treatment. In breast cancer (BC), a multitude of deregulated long noncoding RNAs (lncRNAs) have been identified as potential therapeutic targets also in the context of antiestrogen resistance, and the RNA binding activity of the estrogen receptor α (ERα) points additional potential candidates to interfere with estrogenic signaling. …”
    Get full text
    Article
  19. 239
  20. 240